Skip to main content
. 2023 Apr 21;25(Suppl B):B171–B176. doi: 10.1093/eurheartjsupp/suad098

Figure 2.

Figure 2

Main controlled clinical trials with gliflozines (empagliflozin and dapagliflozin) in patients with chronic heart failure with reduced or preserved ejection fraction, either diabetic or non-diabetic.